The Lupus Research Alliance applauds the approval by the U.S. Food and Drug Administration of Gazyva® (obinutuzumab) from ...
With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...
The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...
The drug is the only medicine of its kind proven to help patients with lupus nephritis regain full kidney response, the ...
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III ...
Patients with lupus nephritis who received hydroxychloroquine demonstrated a significantly lower risk for glomerular ...
The Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...
Singer Selena Gomez's lupus-related arthritis diagnosis sheds light on how up to 90% of lupus patients experience joint pain, ...
Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Roche Holding AG’s (SIX:RO) Gazyva/Gazyvaro ...